Samorin Veterinary Grade API, designated chemically as isometamidium chloride, enters downstream processing as a dark red to reddish-brown hygroscopic powder. Dry-route handling and sterile-liquid handling are both governed by the molecule’s pH-dependent aqueous solubility, light sensitivity, and electrostatic surface charge. Particle size control, moisture specification, and photostability are not interchangeable across dosage forms because each application route imposes different mechanical stresses, dissolution requirements, and regulatory thresholds.

What Processing Constraints Govern Sterile Injectable Re-Constitution of Isometamidium Chloride?

Sterile dry powder for reconstitution is produced by aseptic filling rather than terminal steam sterilization because the phenanthridinium core is susceptible to hydrolytic and photochemical degradation in dilute aqueous solution. The API is typically pre-dried in a vacuum tray dryer at 35 °C and <10 kPa chamber pressure until loss on drying is ≤1.5 % by Karl Fischer titration according to Ph.Eur. 2.5.12. Dried material is passed through a 500 µm stainless steel sieve to break soft agglomerates before fill. Bulk density variation from 0.28 g/mL to 0.45 g/mL across supply batches requires auger speed adjustment on the filling line to maintain fill weight relative standard deviation <2.0 %. Filling is conducted in an isolator maintained at ≤30 % RH and 20 ± 2 °C because moisture uptake above this threshold produces sticky contact surfaces on toothed auger flights. Amber Type I glass vials with bromobutyl rubber stoppers and aluminium flip-off seals are used because the API is light-sensitive; container closure integrity is verified according to USP <1207>. In-process controls include fill weight, moisture, and reconstitution time into Water for Injection. Sterility is tested by Ph.Eur. 2.6.1, bacterial endotoxins by Ph.Eur. 2.6.14, and particulate contamination by Ph.Eur. 2.9.19 after reconstitution. If a lyophilized formulation is selected instead of neat API fill, the filtration step uses a 0.22 µm PVDF membrane, and the freeze-drying cycle typically holds the product at −40 °C during freezing, −20 °C and 150 µbar during primary drying, and 25 °C during secondary drying. The chosen route must be validated because published forced degradation data for this specific molecule in the presence of bulking agents such as mannitol or trehalose is limited.

Batch-to-batch variance in residual moisture has a direct effect on reconstitution behavior. If moisture exceeds 2.0 %, the dry cake or powder can form a tacky film on the vial walls during storage, increasing reconstitution time beyond 60 s. Therefore, the discharge port of the drying tray and the transfer line into the isolator are both maintained under nitrogen purge at 0.2–0.5 bar. The terminal labelled product is a single-dose or multidose veterinary parenteral preparation. For multidose vials, antimicrobial effectiveness must satisfy Ph.Eur. 5.1.3, but the selected preservative must not react with the cationic aromatic system; benzyl alcohol is commonly screened first, followed by compatibility storage at 25 ± 2 °C and 60 ± 5 % RH for six months. If no preservative is used, the vial is filled as a single dose, and the label must prohibit partial reuse. Operational incompatibility is documented with strong oxidizing agents, particularly hydrogen peroxide residues from isolator decontamination; residual concentrations must be below the limit of detection by low-range peroxide test strips before filling starts.

Manufacture of a ready-to-use injectable solution rather than a dry powder shifts the critical control point from moisture to photochemical degradation and pH drift. Isometamidium chloride is first dissolved in Water for Injection at 25–35 °C under low-shear agitation. The vehicle pH is adjusted to 4.0–5.5 with dilute hydrochloric acid or a citrate buffer because solubility declines and the free base can precipitate above pH 5.5. Tonicity is adjusted with sodium chloride to 280–320 mOsmol/kg. The solution is passed sequentially through a 0.45 µm prefilter and a 0.22 µm PVDF sterilizing filter under nitrogen pressure of 0.5–1.0 bar. Terminal steam sterilization at 121 °C for 15 min is not applied without forced degradation data because colour shift from deep red to brown is observed in some aqueous stress studies; aseptic filtration followed by filling under inert headspace is therefore the standard manufacturing path. Amber Type I or Type II glass containers are used, and the headspace oxygen is controlled to <2.0 % with nitrogen flushing. Photostability testing follows VICH GL5, using a xenon light source with ultraviolet filters. Clarity is measured by Ph.Eur. 2.2.1, colour by Ph.Eur. 2.2.2, pH by Ph.Eur. 2.2.3, sub-visible particles by Ph.Eur. 2.9.19, and sterility by Ph.Eur. 2.6.1. The ready-to-use solution must not be mixed with alkaline veterinary products or with anionic surfactants because charge interactions can produce immediate precipitation.

Dry Granulation Routes for High-Dose Veterinary Bolus Tablets

Veterinary bolus tablets containing isometamidium chloride at high unit doses are manufactured by dry granulation to avoid exposing the API to heat and moisture during aqueous wet granulation. Direct compression is possible only if the API particle size distribution has a d90 below 180 µm and bulk density above 0.35 g/mL; otherwise, dry granulation by roller compaction is required. A roller compactor with 250 mm roll diameter and serrated rolls is operated at 6–12 kN/cm roll pressure and 2.0 mm gap width. The ribbon is milled through a 0.8–1.0 mm screen to produce granules with a d50 of 200–400 µm. Fines below 75 µm are controlled to <20 % because electrostatic fines segregate during tablet compression. The dry granulation blend typically contains 15–35 % w/w isometamidium chloride, 45–60 % w/w microcrystalline cellulose, 20–30 % w/w lactose monohydrate, 2–5 % w/w crospovidone, and 1–2 % w/w sodium stearyl fumarate. Magnesium stearate is avoided or minimised because its hydrophobic film can reduce dissolution of a water-soluble API when mixed at high shear for prolonged periods.

Compression is performed on a rotary tablet press with precompression force of 2–5 kN and main compression force of 12–25 kN. Press speed is held at 30–60 rpm to balance dwell time and tablet hardness. Tablet breaking force is maintained at 60–120 N according to USP <1217>. Friability is ≤1.0 % after 100 revolutions, and disintegration is ≤15 min in 0.1 M HCl at 37 °C when tested by USP <701>. Dissolution testing uses USP <711> Apparatus 2 at 50 rpm in 900 mL of pH 4.5 acetate buffer at 37 ± 0.5 °C. The tablet core is then film-coated with a light-barrier coating containing titanium dioxide and iron oxide to reduce photodegradation. Aqueous film coating is applied in a perforated pan at inlet temperature 60–70 °C, product bed temperature 38–42 °C, pan speed 2–6 rpm, spray rate 3–5 g/min, and atomising air pressure 1.5–2.5 bar. Coating weight gain is 3.0–4.5 % w/w. Batch-to-batch granule bulk density variation from 0.42 g/mL to 0.58 g/mL changes fill depth and tablet weight variation; automatic weight control feedback is therefore required on the press.

Hard capsule filling of isometamidium chloride is selected when dose titration in small ruminants requires a lower unit dose than a tablet press can reliably deliver without excessive excipient dilution. The API is pre-sieved through a 500 µm screen and pre-dried at 35 °C to ≤1.0 % loss on drying before blending. A typical direct-fill blend contains 10–30 % w/w isometamidium chloride, 49–70 % w/w mannitol or lactose monohydrate, 2–4 % w/w croscarmellose sodium, 0.5–1.0 % w/w colloidal silicon dioxide, and 1–2 % w/w sodium stearyl fumarate. Blending is performed in a 300 L bin blender at 12 rpm for 15 min. Stratified sampling at 10–12 locations is used to confirm blend uniformity with relative standard deviation ≤5.0 %. If the uniformity fails, mixing is extended in 5 min increments because prolonged blending can increase electrostatic adhesion of the API to blender walls. Encapsulation is performed on a dosator-type machine with pin diameter 7–9 mm and low compression force 5–15 N to avoid plug lamination. Size 1 HPMC capsules are preferred over gelatin because gelatine crosslinking from residual aldehydes can delay dissolution. Fill weight is typically 250–350 mg. The filling suite is held at ≤30 % RH and 20–22 °C; HPMC shell moisture below 3 % w/w causes brittleness, while moisture above 6 % w/w increases closure deformation. Dissolution testing follows USP <711> Apparatus 1 at 100 rpm in 900 mL of pH 4.5 acetate buffer. Content uniformity is evaluated by USP <905> with acceptance value <15.0. The finished capsules are sealed in amber PVC/PVDC/Alu blisters to reduce actinic degradation.

Oral Powder and Granule Reconstitution Profiles Under Tropical Storage

Oral powders and granules containing isometamidium chloride are prepared by fluid-bed granulation when the dosage must be dispersed on feed or reconstituted in water immediately before administration. A top-spray fluid-bed granulator with 40 kg working capacity is charged with the API and diluents, then sprayed with an aqueous binder solution containing 5 % w/w povidone K29/32 or 4 % w/w hydroxypropyl cellulose. Inlet air temperature is set at 60–70 °C, product temperature at 35–42 °C, and spray rate at 200–400 g/min. The granulation endpoint is reached when the moisture content by loss on drying is ≤2.0 % according to USP <731>. The dried granules are screened to a target fraction of 180–710 µm at ≥80 %. Bulk density and flowability are controlled by USP <1174>; granules with flow time faster than 10 s through a 25 mm orifice are acceptable for high-speed sachet filling. Low-moisture conditions in the granulator discharge prevent re-agglomeration, and product temperature is reduced to 25 °C before discharge.

The finished powder or granule is filled into sachets on a vertical form-fill-seal machine using a laminate of PET 12 µm / Al 20 µm / PE 40 µm. Seal temperature is 150–170 °C, seal width 0.8–1.2 mm, and dwell time 0.5–1.0 s. The barrier film is specified with water vapour transmission rate below 0.01 g/m²/day by ASTM F1249 and oxygen transmission rate below 0.05 cm³/m²/day by ASTM D3985. Sachet leakage is tested by vacuum dye penetration at −0.8 bar. Because isometamidium chloride is bitter, oral powders may require palatability masking with apple or molasses flavour. However, flavour ingredients containing reducing aldehydes can react with the aromatic system, so forced degradation storage at 40 ± 2 °C and 75 ± 5 % RH for 1 month is required before formulation lock. Premix compatibility with feed top-dressing is not assumed; direct application onto fermented feeds with acidic pH below 4.0 may accelerate dissolution but does not remove the light-protective packaging requirement.

When Isometamidium Chloride Is Distributed in Medicated Feed Premix

Feed-route administration of isometamidium chloride is not the primary label route, and the decision to prepare a medicated feed premix must be supported by national approval, target animal safety, residue, and efficacy data for the specific indication. Published pharmacokinetic data for oral isometamidium chloride in cattle is limited, so premix development is restricted to jurisdictions where such use is explicitly authorised. When a premix is required, the API is diluted stepwise from 1:10 to 1:100 and then to 1:1000 using ground corn cob or wheat middlings as carrier. A light mineral oil at 0.5–1.0 % w/w is applied to the carrier to reduce dust and electrostatic adhesion of the API. Mixing is performed in a horizontal ribbon mixer with 500 kg capacity and fill coefficient 0.6–0.7. Ribbon speed is 25–35 rpm. Samples are withdrawn at 3 min, 10 min, and 15 min from 10 points using a sampling thief. The coefficient of variation must be ≤5.0 % for active distribution. If the coefficient of variation remains above 5.0 %, the carrier particle size distribution and oil coating uniformity are retested before increasing mixing time.

Assay of isometamidium chloride in feed matrices by HPLC may require an ion-pair reagent because the cationic phenanthridinium structure binds to silanol residues on C18 columns. Extraction recovery should be 90–110 % from spiked blank premix. Pelletised feeds containing the premix are not automatically stable: conditioning at 70–80 °C may cause assay loss exceeding 10 %. If pelleting is unavoidable, the process should be maintained below 60 °C with short residence time, and the pelletised product must be assayed after cooling and drying. Equipment cleaning validation uses HPLC swab recovery of ≥70 % and carryover below 1.0 % of the lowest active concentration. Regulatory compliance for medicated feed premises follows EU Regulation 2019/4 and, for export to the United States, 21 CFR 225.65. Electrostatic adhesion of the API to mixer surfaces is a known production failure; grounding of the mixer and atmospheric humidity control at 35–45 % RH reduce dust without creating wet bridges.

Oral solution concentrates for drench administration are prepared when a liquid dose must be delivered through a drenching gun or mixed into a small volume of drinking water. Isometamidium chloride is dissolved in purified water acidified to pH 4.0–5.0 with citric acid or dilute hydrochloric acid. Propylene glycol at 5–10 % v/v may be added as a cosolvent and density modifier. Sodium benzoate at 0.1 % w/v or potassium sorbate at 0.1 % w/v is screened as a preservative for multiuse containers. Mixing is performed in a high-shear vessel at 500–1000 rpm for 15 min with controlled vortex reduction to avoid excessive aeration. The solution is filtered through a 10 µm clarifying cartridge and then a 2 µm cartridge before filling. Filling into amber PET bottles is performed under nitrogen flush with residual headspace oxygen below 2.0 %. The filled containers are induction-sealed and labelled for storage at 25 °C and 60 % RH. A pH drift greater than 0.5 units during stability indicates hydrolysis or excipient interaction. If crystals form below 5 °C, warming to 25 °C with gentle mixing is required before dose administration. Deliverable volume is tested by USP <698>. This oral solution route is not interchangeable with the parenteral solution because the preservative and cosolvent system does not automatically meet sterility and endotoxin requirements without further aseptic processing.